学术探索
学术期刊
新闻热点
数据分析
智能评审

ROXITHROMYCIN - A NEW MOLECULE, A NEW PHARMACOKINETIC PROFILE

被引：5
作者：
NILSEN, OG
机构：
[1] Department of Pharmacology and Toxicology, Faculty of Medicine, University of Trondheim, Trondheim
[2] University of Trondheim, Trondheim
来源：
DRUG INVESTIGATION | 1991年 / 3卷
关键词：
D O I：
10.1007/BF03258332
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Roxithromycin is one of the newer macrolide antibiotics, and displays a superior gastrointestinal absorption, higher plasma concentrations and a longer plasma half-life than its analogue, erythromycin, thereby permitting once- or twice-daily administration. Its tissue distribution is extensive because of its high lipid solubility, and penetration into the respiratory tract tissues is adequate and comparable to that seen with erythromycin. Roxithromycin's intracellular penetration is superior to that of erythromycin, conferring bactericidal efficacy against intracellular pathogens such as Chlamydia and Legionella pneumophila. Roxithromycin displays nonlinear pharmacokinetics, with no appreciable accumulation and a low propensity for drug interactions.
引用
收藏
页码：28 / 32
页数：5
相关论文
共 25 条
  • [11] Kees F., Grobecker H., Fourtillan J.B., Tremblay D., Saint-Salvi B., Comparative pharmacokinetics of single dose roxithromycin (150mg) versus erythromycin stéarate (500mg) in healthy volunteers, British Journal of Clinical Practice, 42, (1988)
  • [12] Larrey D., Funck-Brentano C., Breil P., Vitaux J., Theodore C., Et al., Effects of erythromycin on hepatic drug-metabolising enzymes in humans, Biochemical Pharmacology, 32, pp. 1058-1063, (1983)
  • [13] Lebrec D., Benhamou J.P., Fourtillan J.B., Tremblay D., Roxithromycin: pharmacokinetics in patients suffering from alcoholic cirrhosis, British Journal of Clinical Practice, 42, (1988)
  • [14] Mannisto P.T., Taskinen J., Ottoila P., Solkinen A., Vuorela A., Et al., Fate of single oral doses of erythromycin acistrate, erythromycin stearate and pelleted erythromycin base analysed by mass-spectrometry in plasma of healthy human volunteers, Journal of Antimicrobial Chemotherapy, 21, pp. 33-43, (1988)
  • [15] Mattina R., Bonfiglio G., Bruno E., Gianni A.B., Porcellini A., Distribution of roxithromycin in odontological tissue, (1988)
  • [16] Meirovich C.I., Monkrull H., Strusberg A.M., Brizuela N., Forti I.N., Roxithromycin levels in synovial fluid, British Journal of Clinical Practice, 42, (1988)
  • [17] Nilsen O.G., Comparative pharmacokinetics of macrolides, Journal of Antimicrobial Chemotherapy, 20, pp. 81-88, (1987)
  • [18] Nilsen O.G., Lenfant B., Saint-Salvi B., Pharmacocinetique de la roxithromycine après administration unique et répétée chez l’insuffisant renal, (1988)
  • [19] Nilsen O.G., Saint-Salvi B., Lenfant B., Manuel C., Pharmacokinetics of roxithromycin in the elderly: linearity and repeat dose studies, British Journal of Clinical Practice, 42, pp. 59-60, (1988)
  • [20] Puri S.K., Lassman H.B., Roxithromycin: a pharmacokinetic review of a macrolide, Journal of Antimicrobial Chemotherapy, 20, pp. 89-100, (1987)
123